System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies
categories: Epitope Tags

Mouse Monoclonal to c-Myc / Cellular myelocytomatosis oncogene

9E10 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-433-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-433-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1X-433-C025 Peroxidase 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1X-433-C100 Peroxidase 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1B-433-C025 biotin 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1B-433-C100 biotin 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1F-433-C025 FITC 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1F-433-C100 FITC 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


The c-myc gene (8q24 on human chromosome) is the cellular homologue of the v-myc gene originally isolated from an avian myelocytomatosis virus. The c-Myc protein is a transcription factor (nuclear localization). c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin-dependent kinase, ERK2 and C-Jun N-terminal Kinase (JNK) in cell proliferation and cell cycle regulation. In normal cells the expression of c-Myc is tightly regulated but in human cancers c-Myc is frequently deregulated. c-Myc is also essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells.


The antibody 9E10 can be used to detect the c-Myc tag.

Regulatory Status


Synthetic peptide sequence (AEEQKLISEEDLL) corresponding to the C-terminal region of human c-Myc.

Species Reactivity:

  • Human
  • Recognizes fusion proteins in all species

Negative Species:


  • Flow Cytometry
    Recommended dilution: 1-5 μg/ml
    Application note: Membrane permeabilization is required.
  • Immunoprecipitation
    Recommended dilution: 1-5 μg/ml
    Application note: not suitable for immunoprecipitation of native c-Myc protein
  • Western Blotting
    Recommended dilution: 0,5-2 μg/ml
    Positive control: c-Myc tagged protein
  • Immunohistochemistry (paraffin sections)
    Recommended dilution: 5-10 μg/ml
    Positive tissue: perfused brain sections, liver, spleen
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21(21): 3414-3421.
  • Boxer LM, Dang CV. 2001. Translocations involving c-myc and c-myc function. Oncogene 20(40):5595-5610.
  • Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. 1999. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253(1): 63-77.
  • Prendergast GC. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18(19):2967-2987.
  • Spandidos DA et al. 1987. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res 7:1299-304.
  • Evan GI et al. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-6.
  • Persson H, Hennighausen L, Taub R, DeGrado W, Leder P: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science. 1984 Aug 17;225(4663):687-93. [Abstract]
  • Product Specific References

  • *Siegel J, Brandner G, Hess RD: Cross-reactivity of the monoclonal antibody 9E10 with murine c-MYC. Int J Oncol. 1998 Dec;13(6):1259-62. [Abstract]
  • * Hilpert K, Hansen G, Wessner H, Kuttner G, Welfle K, Seifert M, Hohne W: Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Eng. 2001 Oct;14(10):803-6. [Abstract]
  • *Baggio R, Burgstaller P, Hale SP, Putney AR, Lane M, Lipovsek D, Wright MC, Roberts RW, Liu R, Szostak JW, Wagner RW: Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit. 2002 May-Jun;15(3):126-34. [Abstract]
  • *Fujiwara K, Poikonen K, Aleman L, Valtavaara M, Saksela K, Mayer BJ: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. Biochemistry. 2002 Oct 22;41(42):12729-38. [Abstract]
  • *Wang X, Campoli M, Ko E, Luo W, Ferrone S: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004 Nov;294(1-2):23-35. [Abstract]
  • *Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, Benistant C: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. J Cell Biol. 2008 Aug 11;182(3):603-14. [Abstract] [Full Text]
  • *Cermák L, Símová S, Pintzas A, Horejsí V, Andera L: Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells. Roles of transcription Daxx expression, and adhesion molecules. J Biol Chem. 2002 Mar 8;277(10):7955-61. [Abstract] [Full Text]
  • *Jelínková I, Šafaříková B, Vondálová Blanářová O, Skender B, Hofmanová J, Sova P, Moyer MP, Kozubík A, Kolář Z, Ehrmann J, Hyršlová Vaculová A: Biochem Pharmacol. 2014 Dec 1;92(3):415-24. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG1 Isotype Control
  • Example Data


    Fig. 1. Detection of transfected LST-1-c-Myc in HEK-293 cells (red) compared with nontransfected HEK-293 cells (blue) using mouse monoclonal anti-c-Myc (9E10) FITC.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy